Limited access to targeted therapies and immunotherapies as well as the aggressive nature of metastatic or recurrent cervical cancer are a few of the barriers to care that affect patients internationally; especially those who seek treatment in low- and middle-income countries. According to a recent analysis of real-world data, those barriers and access to effective palliative chemotherapy treatments play a role both in patient access to cervical cancer care and survival outcomes. ...